CopenFast trial: Faster-acting insulin Fiasp versus insulin NovoRapid in the treatment of women with type 1 or type 2 diabetes during pregnancy and lactation - a randomised controlled trial

Sidse Kjærhus Nørgaard, Elisabeth Reinhardt Mathiesen, Kirsten Nørgaard, Tine Dalsgaard Clausen, Peter Damm, Lene Ringholm, Sidse Kjærhus Nørgaard, Elisabeth Reinhardt Mathiesen, Kirsten Nørgaard, Tine Dalsgaard Clausen, Peter Damm, Lene Ringholm

Abstract

Introduction: Faster-acting insulin aspart (Fiasp) is approved for use in pregnancy and lactation, but no clinical study has evaluated its effects during this life stage in women with pre-existing diabetes. The aim of the CopenFast trial is to evaluate the effect of Fiasp compared with insulin aspart (NovoRapid) on maternal glycaemic control during pregnancy, delivery and lactation and on fetal growth and infant health.

Methods and analysis: An open-label randomised controlled trial of pregnant women with type 1 or type 2 diabetes including women on multiple daily injection (MDI) therapy or insulin pump therapy. During a 2-year inclusion period, approximately 220 women will be randomised 1:1 to Fiasp or NovoRapid in early pregnancy and followed until 3 months after delivery. At 9, 21 and 33 gestational weeks and during planned induction of labour or caesarean section, women are offered blinded continuous glucose monitoring (CGM) for 7 days. Randomisation will stratify for type of diabetes and insulin treatment modality (MDI or insulin pump therapy, respectively). Health status of the infants will be followed until 3 months of age. The primary outcome is birth weight SD score adjusted for gestational age and gender. Secondary outcomes include maternal glycaemic control including glycated haemoglobin, preprandial and postprandial self-monitored plasma glucose levels, episodes of mild and severe hypoglycaemia, maternal gestational weight gain and weight retention, CGM time spent in, above and below target ranges as well as pregnancy outcomes including pre-eclampsia, preterm delivery, perinatal mortality and neonatal morbidity. Data analysis will be performed according to the intention-to-treat principle.

Ethics and dissemination: The trial has been approved by the Regional Ethics Committee (H-19029966) on 7 August 2019. Results will be sought disseminated in peer-reviewed journals and at scientific meetings.

Trial registration number: NCT03770767.

Keywords: clinical trials; diabetes in pregnancy; general diabetes.

Conflict of interest statement

Competing interests: None declared.

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Figures

Figure 1
Figure 1
Flow chart of the CopenFast trial design.

References

    1. Secher AL, Parellada CB, Ringholm L, et al. . Higher gestational weight gain is associated with increasing offspring birth weight independent of maternal glycemic control in women with type 1 diabetes. Diabetes Care 2014;37:2677–84. 10.2337/dc14-0896
    1. Murphy HR, Bell R, Cartwright C, et al. . Improved pregnancy outcomes in women with type 1 and type 2 diabetes but substantial clinic-to-clinic variations: a prospective nationwide study. Diabetologia 2017;60:1668–77. 10.1007/s00125-017-4314-3
    1. Weissmann-Brenner A, Simchen MJ, Zilberberg E, et al. . Maternal and neonatal outcomes of large for gestational age pregnancies. Acta Obstet Gynecol Scand 2012;91:844–9. 10.1111/j.1600-0412.2012.01412.x
    1. Glinianaia SV, Tennant PWG, Bilous RW, et al. . HbA(1c) and birthweight in women with pre-conception type 1 and type 2 diabetes: a population-based cohort study. Diabetologia 2012;55:3193–203. 10.1007/s00125-012-2721-z
    1. Maresh MJA, Holmes VA, Patterson CC, et al. . Glycemic targets in the second and third trimester of pregnancy for women with type 1 diabetes. Diabetes Care 2015;38:34–42. 10.2337/dc14-1755
    1. Persson M, Pasupathy D, Hanson U, et al. . Birth size distribution in 3,705 infants born to mothers with type 1 diabetes: a population-based study. Diabetes Care 2011;34:1145–9. 10.2337/dc10-2406
    1. Jensen D, Damm P, Moelsted-Pedersen L, et al. . Outcomes in type 1 diabetic pregnancies. Diabetes Care 2004;27:2819–23.
    1. Clausen TD, Mathiesen E, Ekbom P, et al. . Poor pregnancy outcome in women with type 2 diabetes. Diabetes Care 2005;28:323–8. 10.2337/diacare.28.2.323
    1. Clausen TD, Mathiesen ER, Hansen T, et al. . Overweight and the metabolic syndrome in adult offspring of women with diet-treated gestational diabetes mellitus or type 1 diabetes. J Clin Endocrinol Metab 2009;94:2464–70. 10.1210/jc.2009-0305
    1. Ringholm L, Damm P, Mathiesen ER. Improving pregnancy outcomes in women with diabetes mellitus: modern management. Nat Rev Endocrinol 2019;15:406–16. 10.1038/s41574-019-0197-3
    1. Ringholm L, Stougaard EB, Nørgaard SK, et al. . Diabetes management during breastfeeding in women with type 1 diabetes. Curr Diab Rep 2020;20:34. 10.1007/s11892-020-01315-x
    1. Roskjær AB, Andersen JR, Ronneby H, et al. . Dietary advices on carbohydrate intake for pregnant women with type 1 diabetes. J Matern Fetal Neonatal Med 2015;28:229–33. 10.3109/14767058.2014.906577
    1. Jovanovic LG. Using meal-based self-monitoring of blood glucose as a tool to improve outcomes in pregnancy complicated by diabetes. Endocr Pract 2008;14:239–47. 10.4158/EP.14.2.239
    1. Mathiesen ER, Kinsley B, Amiel SA, et al. . Maternal glycemic control and hypoglycemia in type 1 diabetic pregnancy: a randomized trial of insulin aspart versus human insulin in 322 pregnant women. Diabetes Care 2007;30:771–6. 10.2337/dc06-1887
    1. Hod M, Damm P, Kaaja R, et al. . Fetal and perinatal outcomes in type 1 diabetes pregnancy: a randomized study comparing insulin aspart with human insulin in 322 subjects. Am J Obstet Gynecol 2008;198:186.e1–7. 10.1016/j.ajog.2007.08.005
    1. Heise T, Stender-Petersen K, Hövelmann U, et al. . Pharmacokinetic and pharmacodynamic properties of Faster-Acting insulin aspart versus insulin aspart across a clinically relevant dose range in subjects with type 1 diabetes mellitus. Clin Pharmacokinet 2017;56:649–60. 10.1007/s40262-016-0473-5
    1. Russell-Jones D, Bode BW, De Block C, et al. . Fast-acting insulin aspart improves glycemic control in basal-bolus treatment for type 1 diabetes: results of a 26-week multicenter, active-controlled, treat-to-target, randomized, parallel-group trial (onset 1). Diabetes Care 2017;40:943–50. 10.2337/dc16-1771
    1. Buse JB, Carlson AL, Komatsu M, et al. . Fast-acting insulin aspart versus insulin aspart in the setting of insulin degludec-treated type 1 diabetes: efficacy and safety from a randomized double-blind trial. Diabetes Obes Metab 2018;20:2885–93. 10.1111/dom.13545
    1. Klonoff DC, Evans ML, Lane W, et al. . A randomized, multicentre trial evaluating the efficacy and safety of fast‐acting insulin aspart in continuous subcutaneous insulin infusion in adults with type 1 diabetes (onset 5). Diabetes Obes Metab 2019;21:961–7. 10.1111/dom.13610
    1. European Medicines Agency . Fiasp summary of product characteristics [online], 2017. Available: [Accessed 31 Jul 2020].
    1. Fresa R, Visalli N, Di Blasi V, et al. . Experiences of continuous subcutaneous insulin infusion in pregnant women with type 1 diabetes during delivery from four Italian centers: a retrospective observational study. Diabetes Technol Ther 2013;15:328–34. 10.1089/dia.2012.0260
    1. Drever E, Tomlinson G, Bai AD, et al. . Insulin pump use compared with intravenous insulin during labour and delivery: the inspired observational cohort study. Diabet Med 2016;33:1253–9. 10.1111/dme.13106
    1. Dude AM, Niznik C, Peaceman AM, et al. . Evaluation of an intrapartum insulin regimen for women with diabetes. Obstet Gynecol 2020;136:411–6. 10.1097/AOG.0000000000003940
    1. Achong N, Duncan EL, McIntyre HD, et al. . Peripartum management of glycemia in women with type 1 diabetes. Diabetes Care 2014;37:364–71. 10.2337/dc13-1348
    1. Inkster B, Elder J, Alexander C, et al. . Post-partum hypoglycaemia in lactating women with type 1 diabetes: a pilot study using continuous glucose monitoring. Br J Diabetes 2015;15:119–22. 10.15277/bjdvd.2015.026
    1. Riviello C, Mello G, Jovanovic LG. Breastfeeding and the basal insulin requirement in type 1 diabetic women. Endocr Pract 2009;15:187–93. 10.4158/EP.15.3.187
    1. Ringholm L, Roskjær AB, Engberg S, et al. . Breastfeeding at night is rarely followed by hypoglycaemia in women with type 1 diabetes using carbohydrate counting and flexible insulin therapy. Diabetologia 2019;62:387–98. 10.1007/s00125-018-4794-9
    1. Achong N, McIntyre HD, Callaway L, et al. . Glycaemic behaviour during breastfeeding in women with type 1 diabetes. Diabet Med 2016;33:947–55. 10.1111/dme.12993
    1. Colatrella A, Framarino M, Toscano V, et al. . Continuous glucose monitoring during breastfeeding in women with recent gestational diabetes mellitus. Diabetes Technol Ther 2012;14:576–82. 10.1089/dia.2011.0266
    1. Bentley-Lewis R, Goldfine AB, Green DE, et al. . Lactation after normal pregnancy is not associated with blood glucose fluctuations. Diabetes Care 2007;30:2792–3. 10.2337/dc07-1243
    1. Chan A-W, Tetzlaff JM, Altman DG, et al. . SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med 2013;158:200–7. 10.7326/0003-4819-158-3-201302050-00583
    1. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement. Obstet Gynecol 2010;115:1063–70. 10.1097/AOG.0b013e3181d9d421
    1. Stage E, Mathiesen ER, Emmersen PB, et al. . Diabetic mothers and their newborn infants - rooming-in and neonatal morbidity. Acta Paediatr 2010;99:997–9. 10.1111/j.1651-2227.2010.01779.x
    1. Nielsen LR, Pedersen-Bjergaard U, Thorsteinsson B, et al. . Hypoglycemia in pregnant women with type 1 diabetes: predictors and role of metabolic control. Diabetes Care 2008;31:9–14. 10.2337/dc07-1066
    1. Pedersen-Bjergaard U, Pramming S, Thorsteinsson B. Recall of severe hypoglycaemia and self-estimated state of awareness in type 1 diabetes. Diabetes Metab Res Rev 2003;19:232–40. 10.1002/dmrr.377
    1. Seaquist ER, Anderson J, Childs B, et al. . Hypoglycemia and diabetes: a report of a workgroup of the American diabetes association and the endocrine society. Diabetes Care 2013;36:1384–95. 10.2337/dc12-2480
    1. Vestgaard M, Ringholm L, Laugesen CS, et al. . Pregnancy-induced sight-threatening diabetic retinopathy in women with type 1 diabetes. Diabet Med 2010;27:431–5. 10.1111/j.1464-5491.2010.02958.x
    1. Bongiovanni M, Fresa R, Visalli N, et al. . A study of the carbohydrate-to-insulin ratio in pregnant women with type 1 diabetes on pump treatment. Diabetes Technol Ther 2016;18:360–5. 10.1089/dia.2015.0246
    1. Mathiesen JM, Secher AL, Ringholm L, et al. . Changes in basal rates and bolus calculator settings in insulin pumps during pregnancy in women with type 1 diabetes. J Matern Fetal Neonatal Med 2014;27:724–8. 10.3109/14767058.2013.837444
    1. Lemieux P, Yamamoto JM, Donovan LE. Do-it-yourself artificial pancreas system use in pregnant women with type 1 diabetes in a real-world setting: 2 case reports. Can J Diabetes 202110.1016/j.jcjd.2021.01.006
    1. Schütz-Fuhrmann I, Schütz AK, Eichner M, et al. . Two subsequent pregnancies in a woman with type 1 diabetes: artificial pancreas was a Gamechanger. J Diabetes Sci Technol 2020;14:972–3. 10.1177/1932296820906219
    1. Cordua S, Secher AL, Ringholm L, et al. . Real-time continuous glucose monitoring during labour and delivery in women with Type 1 diabetes - observations from a randomized controlled trial. Diabet Med 2013;30:1374–81. 10.1111/dme.12246
    1. Marsál K, Persson PH, Larsen T, et al. . Intrauterine growth curves based on ultrasonically estimated foetal weights. Acta Paediatr 1996;85:843–8. 10.1111/j.1651-2227.1996.tb14164.x
    1. Battelino T, Danne T, Bergenstal RM, et al. . Clinical targets for continuous glucose monitoring data interpretation: recommendations from the International consensus on time in range. Diabetes Care 2019;42:1593–603. 10.2337/dci19-0028
    1. Jensen DM, Damm P, Sørensen B, et al. . Pregnancy outcome and prepregnancy body mass index in 2459 glucose-tolerant Danish women. Am J Obstet Gynecol 2003;189:239–44. 10.1067/mob.2003.441
    1. Vinter CA, Jensen DM, Ovesen P, et al. . Postpartum weight retention and breastfeeding among obese women from the randomized controlled lifestyle in pregnancy (LiP) trial. Acta Obstet Gynecol Scand 2014;93:794–801. 10.1111/aogs.12429
    1. Nørgaard SK, Vestgaard MJ, Jørgensen IL, et al. . Diastolic blood pressure is a potentially modifiable risk factor for preeclampsia in women with pre-existing diabetes. Diabetes Res Clin Pract 2018;138:229–37. 10.1016/j.diabres.2018.02.014
    1. Moustgaard H, Clayton GL, Jones HE, et al. . Impact of blinding on estimated treatment effects in randomised clinical trials: meta-epidemiological study. BMJ 2020;368:l6802. 10.1136/bmj.l6802
    1. Ásbjörnsdóttir B, Ronneby H, Vestgaard M, et al. . Lower daily carbohydrate consumption than recommended by the Institute of medicine is common among women with type 2 diabetes in early pregnancy in Denmark. Diabetes Res Clin Pract 2019;152:88–95. 10.1016/j.diabres.2019.05.012

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera